[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Mali\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":423},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,72,96,124,154,181,209,236,259,281,303,319,338,370,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100595082","the-esophageal-string-test-as-a-diagnostic-screening-tool-for-eosinophilic-esophagitis-among-africans-with-dysphagia-in-mali-and-the-united-states-100595082",false,"NCT07027826","The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States","Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Able to provide informed consent.\n2. Aged 18 to 65 years.\n3. Born in the African continent or their parents were born in Africa,\n4. Exhibiting symptoms of dysphagia and\u002For prior history of food impaction.\n5. Undergoing clinically indicated endoscopy at the NIH Clinical Center (U.S.), Centre Hospitalier Universitaire Gabriel Tour(SqrRoot)(Copyright) (Mali), or other local clinics (Mali) and willing to provide research samples and data.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Recent steroid use (systemic or swallowed\u002Ftopical corticosteroid) within 4 weeks prior to endoscopy.\n2. Recent use of dupilumab (Dupixent) within the last 6 months.\n3. Recent use of other biologic medications (within either 6 months or 5 half-lives, whichever is longer). Examples of biologic medications include:\n\n3a. mepolizumab (Nucala)\n\n3b. reslizumab (Cinqair, Cinqaero)\n\n3c. benralizumab (Fasenra)\n\n3d. cendakimab\n\n3e. tezepelumab (Tezspire)\n\n3f. barzolvolimab\n\n4\\. Individuals suffering from a bleeding diathesis (e.g., hemophilia, severe thrombocytopenia).\n\n5\\. Current use of anticoagulant medications.\n\n6\\. Pregnancy.\n\n7\\. Treatment with another investigational drug or other investigational intervention within 6 months or 5 half-lives whichever is longer.\n\n8\\. Individuals with a known history of any of the following:\n\n8a. eosinophilic esophagitis\n\n8b. esophageal stricture unable to be passed with an upper endoscope\n\n8c. esophageal cancer\n\n8d. esophageal motility disorder (e.g., achalasia)\n\n8e. esophageal varices\n\n8f. esophageal or gastric surgery including fundoplication\n\n8g. neurologic cause of dysphagia (e.g., stroke, Parkinson s disease, etc.)\n\n8h. allergy to gelatin\n\n8i. inability to swallow pills\n\n9\\. Any condition that, in the investigator s opinion, places the individual at undue risk by participating in the study.\n\nCo-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the principal investigator in consultation with the medical monitor. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.","ALL","18 Years","65 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background:\n\nEosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the tube that moves food from the mouth to the stomach. Diagnosing EoE currently requires a specialized tool called an endoscope. The esophageal string test (EST) is another test; the EST collects fluid from the upper digestive tract. An EST is simpler and cheaper than an endoscopy. Researchers want to know if an EST can diagnose EoE.\n\nObjective:\n\nTo test if the EST can diagnose EoE in people who have trouble swallowing.\n\nEligibility:\n\nAdults aged 18 to 65 years with trouble swallowing. They must have been born in the African continent or their parents were born in Africa.\n\nDesign:\n\nParticipants will be screened. They will give blood, stool, urine, and skin swab samples. They will complete surveys about their medical history, diet, symptoms, and home environment. They will bring a sample of their drinking water for testing.\n\nParticipants will have an EST. They will swallow a pill capsule that contains a nylon string. One end of the string will be taped to their cheek. The string will unravel down the esophagus and into the stomach. It will be pulled out after 1 hour. Fluids that soaked into the string will be tested.\n\nAt a different visit, participants will have an endoscopic exam. An endoscope is a flexible tube that is inserted down the mouth; it can be used to take tissue samples from the esophagus, stomach, and small intestine.\n\nParticipants will have a final visit in person, online, or by phone. They will take a survey and talk about their test results.",[27,28],"Dysphagia","Eosinophilic Esophagitis",[28,27,30],"Esophageal string test","RECRUITING","2026-08-24",{"date":34,"type":35},"2026-08-25","ACTUAL",{"date":37,"type":21},"2026-08-30",{"date":39,"type":21},"2027-08-31",{"name":41,"class":42},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":4,"leadSponsor":70,"locationsCount":71},"100145734","host-and-parasite-factors-that-influence-susceptibility-to-malaria-infection-and-disease-during-pregnancy-and-early-childhood-in-ouelessebougou-and-bamako-mali-100145734","NCT01168271","Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali","* INCLUSION CRITERIA:\n\nA study participant must satisfy the following criteria to be or have been enrolled in this study:\n\n1. Pregnant women aged 15-45 years and their newborn infants who are residents of the district of Ouelessebougou for at least one year at the time of enrollment (cohort completed clinical follow up; sample and data analysis ongoing); OR\n2. Children who previously participated in the 1st cohort of \"pregnant women and their newborn infants\", OR\n3. Children aged 3 years or less, who are residents of the district of Ouelessebougou for at least one year at the time of enrollment (cohort completed clinical follow up; sample and data analysis ongoing), OR\n4. Febrile hospitalized children (aged 0-10 years), including those with positive and negative blood smears for P. falciparum in Ouelessebougou or the pediatric service of Gabriel Toure Hospital in Bamako. Febrile non-hospitalized children (aged 0-10 years) with non-severe malaria will be recruited at outpatient clinics in Ouelessebougou district health hospital and nearby facilities, with no chronic or serious illness.\n5. Pregnant women aged 15-25 in Ouelessebougou district health centers or maternity unit of Gabriel Toure Hospital in Bamako and for a case-control study of pregnancy malaria and preeclampsia. Cases include women with signs\u002Fsymptoms of preeclampsia. Control pregnant women without signs\u002Fsymptoms of preeclampsia will be recruited sequentially after identification of individual cases, matched for parity, age (+\u002F-2 years) and pregnancy trimester.(cohort completed clinical follow up; sample and data analysis ongoing)\n6. The study participant or parent\u002Fguardian understands the study and gives informed consent for participation of themselves and\u002For their child, and agrees to have samples stored.\n\nEXCLUSION CRITERIA:\n\nA participant will be excluded from the study if any one or more of the following criteria are met:\n\n1. Chronic, debilitating illness, other than malaria, determined by history and physical examination of mother or study participant.\n2. Conditions that in the judgment of the investigator could increase the risk to the volunteer.\n3. History of previous participation in a malaria vaccine trial.",true,"1 Day","45 Years",{"count":54,"type":21},15000,"OBSERVATIONAL","Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. A greater understanding of the immunologic and parasitologic factors associated with infection and disease is badly needed; and will accelerate the development of highly protective vaccines for both mothers and children. Pregnancy malaria is associated with low birth weight, maternal anemia, and gestational hypertension, and both inflammation and the fetal response to infection may contribute to these poor outcomes. Childhood malaria is a major cause of mortality, and we have found that its risk is related to in utero exposure to pregnancy malaria, as well as other host factors like iron status and constitutive cytokine levels. Pregnancy malaria is caused by a distinct parasite binding phenotype, and as our primary hypothesis in this study we speculate that severe childhood malaria parasites may also have distinct features. A longitudinal cohort study will be conducted in Ouelessebougou, Mali, an area of intense seasonal transmission. Up to 2000 pregnant women and their infants and 2000 children aged 0-3 years will be enrolled and followed to age 5 years, with clinical evaluation and periodic venous and peripheral blood samples being obtained. In addition, up to 3000 febrile hospitalized and non-hospitalized children up to 10 years ofd age will be enrolled at the Ouelessebougou district health centers or the Gabriel Toure Pediatric Hospital in Bamako, Mali, with acute and convalescent samples being obtained and 500 pregnant women enrolled at the health centers and hospital in Ouelessebougou district or the Gabriel Toure Hospital in Bamako for a case-control study on pregnancy malaria and preeclampsia. Up to 1000 children originally enrolled at birth and completed the \"pregnant women and their newborns study\" will be re-enrolled and followed for up to 10 years as they age from later childhood through adolescence to early adulthood. Clinical, parasitologic and host response (including immunologic) endpoints will be analyzed using appropriate statistical methods, including possible confounders, to determine factors associated with infection and disease in pregnant women and young children.",[58],"Malaria",[60,61,62,63,64,65],"Observational","Newborns","Hospitalized","Febrile","Resistance","Natural History","2026-08-21",{"date":32,"type":35},{"date":69,"type":35},"2010-08-30",{"name":41,"class":42},2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":4,"leadSponsor":94,"locationsCount":71},"100057066","study-of-inherited-neurological-disorders-100057066","NCT00004568","Study of Inherited Neurological Disorders","Clinical and Molecular Manifestations of Inherited Neurological Disorders","* Participants include those with inherited neurological conditions based on the training and research needs of the Neurogenetics Branch program. There is no logical limit; however the total number of participants that can be enrolled in the protocol will be restricted. No more than 3,500 participants with either diagnosed or undiagnosed neurological conditions and their unaffected relatives will be enrolled in this evaluation and diagnostic protocol.\n\nINCLUSION CRITERIA:\n\nParticipants will be eligible if they:\n\n* Have either a known or suspected, inherited neurological disease, OR are an unaffected relative (first-, second-, third, or higher degree relative) of a participant with a genetic neurological disease.\n* Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children or a legal guardian to provide consent for adults without consent capacity.\n* Aged 2 years and above.\n\nEXCLUSION CRITERIA:\n\nParticipants will not be eligible if they:\n\n-Have a systemic disease that compromises the ability to provide adequate neurologic examination or diagnosis.An example of this would be a contagious disease that would compromise our ability to do an adequate neurological exam.","2 Years","120 Years",{"count":82,"type":21},3500,"This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development. It will examine the genetics, symptoms, disease progression, treatment, and psychological and behavioral impact of diseases in the following categories: hereditary peripheral neuropathies; hereditary myopathies; muscular dystrophies; hereditary motor neuron disorders; mitochondrial myopathies; hereditary neurocognitive disorders; inherited neurological disorders without known diagnosis; and others. Many of these diseases, which affect the brain, spinal cord, muscles, and nerves, are rare and poorly understood.\n\nChildren and adults of all ages with various inherited neurological disorders may be eligible for this study. Participants will undergo a detailed medical and family history, and a family tree will be drawn. They will also have a physical and neurological examination that may include blood test and urine tests, an EEG (brain wave recordings), psychological tests, and speech and language and rehabilitation evaluations. A blood sample or skin biopsy may be taken for genetic testing. Depending on the individual patient s symptoms, imaging tests such as X-rays, CT or MRI scans and muscle and nerve testing may also be done.\n\nInformation from this study may provide a better understanding of the genetic underpinnings of these disorders, contributing to improved diagnosis, treatment, and genetic counseling, and perhaps leading to additional studies in these areas.",[85,86,87,88],"Motor Neuron Disease","Muscular Disease","Muscular Dystrophy","Peripheral Nervous System Disease",[90,87,85],"Myopathy",{"date":32,"type":35},{"date":93,"type":35},"2000-02-18",{"name":95,"class":42},"National Institute of Neurological Disorders and Stroke (NINDS)",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":103,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":106,"studyType":55,"phases":4,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":123},"100480992","bph-global-registry-100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH","MALE",{"count":105,"type":21},7500,"3 Years","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[109,110],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[112],"BPH, Registry, LUTS","2026-08-11",{"date":115,"type":35},"2026-08-13",{"date":117,"type":35},"2023-03-13",{"date":119,"type":21},"2028-12",{"name":121,"class":122},"Société Internationale d'Urologie","OTHER",30,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100651135","phase-1-safety-tolerability-pharmacokinetics-and-mosquitocidal-activity-of-lotilaner-in-healthy-participants-in-mali-100651135","NCT07758985","Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.","A Phase 1b, Single-Center, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Mosquitocidal Activity of Single Oral Doses of Lotilaner in Healthy Participants in Mali.","Inclusion Criteria:\n\n1. Male and female volunteers aged 18-55 years of age (inclusive) at the time of signing the Informed Consent.\n2. Total body weight (BW) ≥50 kg, and a body mass index (BMI) of 18-32 kg\u002Fm2 (inclusive).\n3. Residence within the study area.\n4. Judged healthy based on a comprehensive clinical assessment, including a detailed medical history and full physical examination.\n5. Axillary temperature \\\u003C37.0ºC without history of fever during the previous week.\n6. Willingness to adhere to the requirement regarding the use of contraception, as per the study protocol\n7. Willingness and ability to adhere to study requirements and to participate and communicate for the duration of the trial.\n8. Agreement to provide current contact details\n\nExclusion Criteria:\n\n1. Evidence of clinically significant, gastrointestinal, cardiac, lung, hepatic, neurologic, psychiatric, rheumatologic, autoimmune, dermatologic, hematological, oncologic, or renal disease by anamnesis, physical examination, and\u002For laboratory tests.\n2. Known Central Nervous System disorders or a history of seizures.\n3. Any surgery that may affect drug bioavailability (excluding appendectomy and cholecystectomy).\n4. Signs and symptoms of uncomplicated or severe malaria. An asymptomatic Plasmodium infection is not exclusionary.\n5. Female who is lactating or pregnant according to the serum pregnancy test at Screening.\n6. History of significant hypersensitivity to lotilaner (including excipients of the formulations) or any related products.\n7. History of a severe allergic reaction or anaphylaxis or severe hypersensitivity reactions to any drugs.\n8. Significant history of drug dependency or alcohol abuse (\\>3 units of alcohol per day, intake of excessive alcohol, acute or chronic).\n9. Participants who are current smokers or have used nicotine-containing products within 90 days prior to study treatment administration.\n10. Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past two years, or that has required the use of oral or parenteral corticosteroids at any time during the past two years).\n11. Known asplenia or functional asplenia.\n12. Known history or evidence of clinically significant cardiovascular abnormalities\n13. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results.\n14. Known diabetes or diabetes identified during screening\n15. Any serious medical condition or abnormality in clinical laboratory tests that, in the opinion of the investigator, precludes the Participant's safe participation in and completion of the study or affects the ability of the Participant to understand and comply with the study protocol.\n16. Prior antimalarial therapy or antibiotics with antimalarial activity (prophylaxis or treatment) within four weeks or five half-lives (whichever is longer) before study drug administration.\n17. Current or recent use of any prohibited medications according to the study protocol\n18. Pre-planned surgery during the study.\n19. Intake of lotilaner in the six months before the study drug administration.\n20. Receipt of any investigational product within the past 30 days or five half-lives (whichever is longer) before screening.\n21. Use of St. John's wort in the 28 days before study treatment administration and through the duration of the study.\n22. Participation or planned participation in an interventional trial with an investigational product before the last required protocol visit.\n23. Treatment with systemic ivermectin within four weeks or five half-lives (whichever is longer) before Screening.\n24. Any individual who, in the judgment of an Investigator, is likely to be non-compliant during the trial, or is unable to cooperate.\n25. Any individual who is an Investigator, research assistant, pharmacist, trial coordinator, or other staff thereof, directly involved in conducting the trial.","55 Years",{"count":133,"type":21},75,[135],"PHASE1","This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy, adult participants living in Mali.",[58],[139,140,141,142,143],"food effect","safety","pharmacokinetics","lotilaner","mosquitocidal activity","NOT_YET_RECRUITING","2026-08-10",{"date":113,"type":35},{"date":148,"type":21},"2026-08",{"date":150,"type":21},"2027-08",{"name":152,"class":122},"Medicines for Malaria Venture",1,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":50,"sex":161,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":153},"100245280","laboratory-evaluation-of-pregnancy-malaria-vaccine-candidatesin-vitro-testing-of-pregnancy-malaria-vaccine-candidates-100245280","NCT02471378","Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates\u002FIn-vitro Testing of Pregnancy Malaria Vaccine Candidates","In-Vitro Testing of Pregnancy Malaria Vaccine Candidates","* INCLUSION CRITERIA:\n\nA study participant must satisfy the following criteria to be enrolled in this study:\n\n* Pregnant women aged 15-25 years\n* Able to provide consent for self\n* Malaria positive by rapid diagnostic test (RDT)\n\nEXCLUSION CRITERIA:\n\n* Severe anemia defined as HGB\\\u003C7 gr\u002FdL, that may be worsened by 10 mL phlebotomy\n* Conditions that in the judgment of the investigator could increase the risk to the volunteer\n* Prior enrollment to the study during the same pregnancy","FEMALE","15 Years","25 Years",{"count":165,"type":21},7476,"Background:\n\n\\- Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away. Children younger than 5 and pregnant women are most at risk to get malaria. Researchers want to create a vaccine that will prevent malaria infection during pregnancy.\n\nObjectives:\n\n\\- To create a vaccine that will prevent malaria infection during pregnancy. To assess possible vaccines using in-vitro tests with parasites taken from pregnant women.\n\nEligibility:\n\n\\- Pregnant women ages 15-25\n\nDesign:\n\n* The study site is an area in Mali, West Africa.\n* Participants:\n* Will have blood drawn.\n* Will give consent for the blood sample to be used for future research.\n* May have a physical exam.\n* Participants who have malaria or anemia will get treatment.",[58],[169,170,171,172,173,65],"Assays","Women","Infected","Antibodies","Plasmodium Falciparum","2026-08-07",{"date":145,"type":35},{"date":177,"type":35},"2015-07-28",{"date":179,"type":21},"2028-06-30",{"name":41,"class":42},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":50,"sex":161,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":153},"100644937","phase-2-pfspz-larc2-vaccine-in-women-of-child-bearing-potential-wocbp-in-mali-100644937","NCT07675785","PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali","Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, & Protective Efficacy of Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) in Healthy African Adult Women of Childbearing Potential in Mali","Inclusion Criteria:\n\n1. Females of childbearing potential aged ≥ 18 and ≤ 38 years\n2. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n3. In good general health and without clinically significant medical history\n4. Willing to have blood samples stored for future research\n5. Available for the duration of the study\n6. Must be willing to use reliable contraception (defined as: pharmacologic contraceptives \\[parental delivery\\] or pre-existing intrauterine or implantable device) from 21 days prior to first vaccination (study day 1) to 28 days after last vaccination (study day 57)\n7. Willingness to undergo HIV testing\n8. Report being interested in becoming pregnant within the next 1 year\n\nExclusion Criteria:\n\n1. Pregnancy at the time of enrollment\u002Fvaccination, as determined by a positive urine or serum human chorionic gonadotropin (β-hCG) test\n2. Biologically unable to become pregnant secondary to: surgical sterilization, premature ovarian insufficiency (defined as no menses for ≥12 months without an alternative medical cause)\n3. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and comply with the study protocol\n4. Hemoglobin (Hgb), WBC, absolute neutrophils, and platelets outside the local laboratorydefined limits of normal and ≥ Grade 2 (participants may be included at the investigator's discretion for 'not clinically significant' abnormal values)\n5. Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal and ≥ Grade 2 (participants may be included at the investigator's discretion for 'not clinically significant' abnormal values)\n6. Infected with human immunodeficiency virus (HIV)\n7. Known or documented sickle cell disease by history (Note: known sickle cell trait is NOT exclusionary)\n8. Clinically significant abnormal electrocardiogram (ECG) such as abnormal QTc.\n9. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and\u002For laboratory studies including urinalysis\n10. History of receiving any investigational product within the past 30 days\n11. Participation or planned participation in a clinical trial with an investigational product prior to completion of the follow-up visit 28 days following last vaccination OR planned participation in an investigational vaccine study until the last required protocol visit\n12. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months\n13. History of a severe allergic reaction (Grade 2 or higher or per PI discretion) or anaphylaxis\n14. Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past two years, or that has required the use of oral or parenteral corticosteroids at any time during the past two years)\n15. Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia\n16. Known immunodeficiency syndrome\n17. Known seizure disorder or history of seizures (exclusion: simple febrile seizure during childhood) or history of migraine headaches\n18. Laboratory evidence of hepatitis B or C\n19. Known asplenia or functional asplenia\n20. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone ≥20 mg\u002Fday) or immunosuppressive drugs within 30 days of vaccination\n21. Receipt of a live vaccine within the past four weeks or a killed vaccine within the past two weeks prior to Vaccination #1 and every subsequent vaccination day\n22. Receipt of immunoglobulins and\u002For blood products within the past six months\n23. Previous receipt of an investigational malaria vaccine in the last ten years\n24. Known allergies or other contraindications against use of artemether\u002Flumefantrine\n25. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a participant participating in the trial, interfere with the evaluation of the study objectives, or would render the participant unable to comply with the protocol","38 Years",{"count":190,"type":21},300,[192],"PHASE2","A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10\\^5 PfSPZ or placebo in healthy WOCBP, who are on pregnancy prevention during vaccination, but report plans to become pregnant in the near future.\n\nParticipants will be randomized into two arms. Arm 1: (n= 150) will receive 3 doses of PfSPZ-LARC2 Vaccine (2x10\\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 6, 29 days.\n\nArm 2: (n= 150) will receive 3 doses of normal saline (placebo) injection via DVI at 1, 6, 29 days.\n\nAll volunteers will receive antimalarial treatment with artemether\u002Flumefantrine (AL) \\~2 to 4 weeks prior to 1st (study day -14 to -28) and \\~2 weeks prior to 3rd injection (study day 44). Participants will be monitored for safety, tolerability, immunogenicity, and malaria infection during the follow-up period. Participants will also be monitored closely for pregnancy as well post 3rd injection through the entire planned study duration (2 years post dose 1). If pregnant, women will be followed during the course of their pregnancy and for at least 1 year post-delivery (as well as their offspring) for safety and malaria infection. Malaria infections in participants and their offspring will be classified as asymptomatic or symptomatic (clinical cases).",[195],"Malaria (Plasmodium Falciparum)",[197,198],"PfSPZ-LARC2 Vaccine","malaria","2026-07-22",{"date":201,"type":35},"2026-07-23",{"date":203,"type":35},"2026-07-20",{"date":205,"type":21},"2030-04",{"name":207,"class":208},"Sanaria Inc.","INDUSTRY",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":50,"sex":16,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":51,"studyType":55,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":71},"100622094","evaluation-of-the-antibody-persistence-beyond-five-years-after-immunization-with-menfivetm-nmcv-5-a-pentavalent-meningococcal-acywx-conjugate-vaccine-100622094","NCT07379151","Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","Evaluation of the Antibody Persistence in African Participants Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","PERS-ACYWX-03","Inclusion Criteria:\n\n* Written informed consent and assent (if applicable)\n\nExclusion Criteria:\n\n* Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination\n* Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study","7 Years","36 Years",{"count":220,"type":21},450,"This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.",[223],"Meningoccocal Disease",[225,226],"Seropersistence","Meningococcal","2026-05-29",{"date":229,"type":35},"2026-06-03",{"date":231,"type":35},"2026-05-05",{"date":233,"type":21},"2026-12",{"name":235,"class":208},"Serum Institute of India Pvt. Ltd.",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":50,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":71},"100596932","microbiome-and-atopy-in-mali-100596932","NCT07051902","Microbiome and Atopy in Mali","Analyzing the Microbiome and Environmental Exposures of Patients Suffering From Atopic Diseases in Mali","Inclusion Criteria (Study Group):\n\n* Aged ≥3 years.\n* Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \\\u003C18 years).\n* Positive Screening questionnaire for asthma or eczema.\n* Diagnosed with atopic dermatitis or asthma via physician diagnosis and criteria as follows:\n* Clinical diagnosis of atopic disease, as defined by Hanifin and Rajka criteria, that has been present for ≥3 months before the screening visit.\n\nInclusion Criteria (Healthy Volunteers):\n\n* Aged ≥3 years.\n* Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \\\u003C18 years).\n* Negative Screening questionnaire for asthma and eczema.\n* In good general health as evidenced by medical history and not diagnosed with atopic dermatitis or asthma via physician diagnosis.\n* Failure to meet Hanifin and Rajka criteria and \\\u003C3 on GINA guidelines for asthma diagnosis.\n* No self-reported history of food allergy.\n\nExclusion Criteria:\n\n* Use of antibiotics in the 3 months prior to screening.\n* Current pregnancy or lactation (determined by self-report).\n* Treatment with an investigational drug within 12 months prior to screening.\n* Current smoker or tobacco use within 4 months prior to screening.\n* Current skin infections other than atopic dermatitis (e.g., scabies).\n* Active diarrhea as defined by three or more loose stools per day (Bristol stool scale score of 6 or 7).\n* Presence of current bacterial, viral, or fungal infection, with the exception of isolated onchomycosis, which is not exclusionary.\n* Any other condition or factor that the investigator determines may significantly influence the results of testing.",{"count":244,"type":21},288,"This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes. In this study, the investigators will look for clues about things that may affect whether people get allergic diseases. The investigators will look at things on or in the body, like germs, and things in the environment, like pollution. To do this, the investigators will collect different types of biological samples, health information, and environmental information from people with allergic diseases and people without allergic diseases. The investigators will compare what is found in each group to look for differences that might be related to allergic disease.",[247],"Atopic Disease",[249,250,251],"asthma","atopic dermatitis","allergies","2026-04-10",{"date":254,"type":35},"2026-04-15",{"date":256,"type":35},"2025-09-30",{"date":233,"type":21},{"name":41,"class":42},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":50,"sex":161,"minAge":162,"maxAge":266,"enrollmentInfo":267,"targetDuration":269,"studyType":55,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":153},"100552071","pregnancy-registry-in-mali-100552071","NCT06468319","Pregnancy Registry in Mali","Assessment of Pregnancy Outcomes Through Demographic Surveillance and Prospective Data Collection at a Health Facility in Kalifabougou, Mali","Inclusion Criteria:\n\nCommunity Census Cohort:\n\n1. Females of childbearing potential or pregnant females.\n2. Aged 15 to 49 years.\n3. Able to provide verbal individual informed consent.\n\nHealth Facility Cohort:\n\n1. Pregnant females 15 to 49 years and their subsequent offspring.\n2. Resides in or in the health catchment area of Kalifabougou and willing to return to the health center for Antenatal Care (ANC) visits.\n3. Able to provide written individual informed consent for herself and her future offspring(s).\n\nExclusion Criteria:\n\nCommunity Census Cohort:\n\n1. Temporary residence in the study area.\n2. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of an individual participating in the study, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.\n\nHealth Facility Cohort:\n\n1. Temporary residence in the study area.\n2. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of an individual participating in the study, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.","49 Years",{"count":268,"type":21},9500,"5 Years","This registry will assess pregnancy outcomes through demographic surveillance and prospective data collection at a health facility in Kalifabougou, Mali.",[58,272],"Pregnancy Related","2026-03-11",{"date":275,"type":35},"2026-03-13",{"date":277,"type":35},"2024-08-05",{"date":279,"type":21},"2030-06",{"name":41,"class":42},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":288,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},"100395158","therapeutic-recommendations-for-the-treatment-of-children-with-a-retinoblastoma-100395158","NCT04425434","Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma","GFARB12019","Inclusion Criteria:\n\n* Unilateral intraocular Retinoblastoma (RB)\n* Unilateral extraocular intraorbital (RB)\n* Bilateral intraocular (RB)\n* bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.\n\nExclusion Criteria:\n\n* Externalized tumor mass\n* massive extension to optic nerve up to optical channeltumor\n* intracranial extension leptomeninges\n* cerebral parenchyma\n* extension to regional lymph nodes and\u002For remote metastases.\n* cerebrospinal fluid involvement.\n* Trilateral RB\n* Incapacity to followed the whole treatement.",{"count":289,"type":21},3000,"As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.",[292],"Retinoblastoma","2026-02-27",{"date":295,"type":35},"2026-03-02",{"date":297,"type":35},"2020-11-01",{"date":299,"type":21},"2030-12-31",{"name":301,"class":122},"French Africa Pediatric Oncology Group",7,{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":310,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":318,"locationsCount":302},"100395157","recommendations-for-the-treatment-of-children-with-burkitts-lymphoma-100395157","NCT04425421","Recommendations for the Treatment of Children With Burkitt's Lymphoma","GFALMB2019","Inclusion Criteria:\n\nClinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.\n\n\\-\n\nExclusion Criteria:\n\nNot a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.",{"count":311,"type":21},1000,"This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.",[314],"Burkitt Lymphoma",{"date":295,"type":35},{"date":297,"type":35},{"date":299,"type":21},{"name":301,"class":122},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":327,"maxAge":17,"enrollmentInfo":328,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":302},"100395008","therapeutic-recommendations-for-nephroblastoma-100395008","NCT04423484","Therapeutic Recommendations for Nephroblastoma","Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.","GFANEPHRO20","Inclusion Criteria:\n\nUnilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.\n\n.\n\nExclusion Criteria:\n\nBilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal","6 Months",{"count":311,"type":21},"The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.",[331],"Nephroblastoma",{"date":295,"type":35},{"date":334,"type":35},"2020-07-01",{"date":336,"type":21},"2030-12-30",{"name":301,"class":122},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":161,"minAge":346,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":368,"locationsCount":43},"100590046","phase-3-safety-of-antimalarials-in-the-first-trimester-100590046","NCT06962319","Safety of Antimalarials in the FIRst trimEster","A Multicentre Open-label, Non-inferiority Adaptive Platform Randomised Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Antimalarials for the Treatment of Uncomplicated Malaria in the First Trimester of Pregnancy: Master Protocol","SAFIRE","Inclusion Criteria:\n\n* ≥2 weeks and \\\u003C14 weeks (13-6\u002F7 weeks inclusive) gestation from the last menstrual period (LMP) as assessed by echography\n* Microscopy confirmed P. falciparum mono or mixed infections, regardless of symptoms.\n* Emancipated minor and aged ≥16 years\n* Haemoglobin ≥ 7 g\u002FdL\n* Residence within the health facility catchment area\n* Willingness to adhere to study requirements and to deliver the baby at the local health facility\n* Willingness to adhere to study requirements and to deliver the baby at the local health facility\n\nExclusion Criteria:\n\n* Known allergy to any of the study drugs\n* History of known pregnancy complications or poor obstetric history, such as repeated miscarriages, stillbirths, or eclampsia\n* History or presence of major illnesses likely to influence pregnancy outcome\n* Known HIV positive\n* Any significant illness at the time of screening requiring hospitalisation, including severe malaria\n* Intent to move out of the study catchment area before delivery or planned delivery out of the catchment area\n* Recent (2 weeks) treatment with antimalarials or antimicrobials with antimalarial activity (chloroquine, AL, DP, PA, SPAQ, ASAQ, MQAS, azithromycin, clindamycin, tetracycline, quinolones, cotrimoxazole and SP)\n* Twin\u002Fmultiple pregnancy detected\n* Non-viable pregnancy confirmed by ultrasound or doppler\n* Known history or evidence of clinically significant cardiovascular disorders or family history of sudden death or congenital long QT syndrome or current co administration of other drugs that might contribute to a prolonged QTc interval or cause \"Torsades de Point\"\n* Chronic medical condition requiring frequent medications (e.g., TB, suspected hepatic lesions, liver disease, sickle cell disease, diabetes, epilepsy, asthma and hypertension)\n* Prior randomisation in this study during the current pregnancy","16 Years",{"count":348,"type":21},1510,[350],"PHASE3","The SAFIRE study aims to find effective treatments with acceptable safety for malaria in early pregnancy, a particularly sensitive time for the adverse consequences of malaria in pregnancy for both mother and baby. Currently, WHO recommends the antimalarial drug artemether-lumefantrine (AL) for the treatment of uncomplicated malaria in the first trimester of pregnancy. Other promising treatments are being rolled out in malaria-endemic countries for use in adults and children and data on current exposures in the first trimester are limited and insufficient to support a recommendation. This is due to the fact that pregnant women are often excluded from clinical trials to protect fetuses, unintentionally depriving them of newer, potentially better treatments. Instead, they often received older, less effective drugs. The International Council for Harmonisation (ICH E21) and stringent regulatory authorities (e.g. EMA, FDA and MHRA) now encourage pregnant women to be included in well-designed studies to ensure they can safely benefit from medical advances.\n\nThis study will compare AL with the newer antimalarial drugs that have shown no significant safety concerns in laboratory studies, accidental use during early pregnancy, or trials in later pregnancy stages. The main goal is to see if these new drugs work as well as AL in treating malaria and are safe for the mother, her pregnancy and the developing baby. The newer antimalarials being tested also offer additional benefits to pregnant women, such as preventing new malaria infections for longer after treatment than the current standard treatment (AL). Also, they can be taken just once a day instead of twice daily, like AL. A simpler dosing schedule could improve adherence to the study medication, meaning women are more likely to take the full course of treatment as prescribed. This, in turn, enhances its effectiveness in real-world settings. Future antimalarials to be tested will include those with improved resistance profiles, offering more effective options for combating drug-resistant strains.\n\nSAFIRE uses a special \"Bayesian Adaptive Platform Trial\" (APT) design. This open-ended approach allows researchers to add new interventions under the same protocol, leveraging the existing trial network with infrastructure. The use of a common protocol with innovative adaptive statistical design allows the trial to stop early if it becomes clear that the new drugs are unsafe.\n\nThis multi-centre trial will be conducted in several countries in Africa where malaria is very common. Women will be randomly assigned to receive either AL or one of the new treatments. Participants will be seen daily for 4 days, then weekly for 6 weeks to assess the response to treatment, and then monthly until delivery. Their health and outcomes will be closely monitored during and after pregnancy. Newborns will be followed for 6 months. An independent data safety and monitoring board (DSMB) will regularly monitor safety data as it accumulates. By finding more treatment options, this study could improve care for pregnant women with malaria and lead to better health for mothers and babies in areas where malaria is widespread. The results will help inform global health policies and potentially change how we treat malaria in early pregnancy.",[353,354,355],"Malaria, Pregnancy","Malaria, Antepartum","Malaria (Uncomplicated)",[58,357,358,359,360,361],"Pregnancy","First trimester","antimalaria","artemether-lumefantrine","Adaptive Platform Trial","2025-11-18",{"date":364,"type":35},"2025-11-19",{"date":256,"type":35},{"date":367,"type":21},"2029-08",{"name":369,"class":122},"Liverpool School of Tropical Medicine",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":17,"enrollmentInfo":378,"targetDuration":380,"studyType":55,"phases":4,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":392},"100347437","hospital-based-registry-of-childhood-cancer-in-pediatric-oncology-units-in-french-speaking-africa-100347437","NCT03803735","Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa","French African Pediatric Oncology Registry","RFAOP","Inclusion Criteria:\n\n1. Any child presenting at any one of the participating units for treatment\n2. Any child with any type of cancer\n3. Any child or adolescent less than 18 years of age.\n\nExclusion Criteria:\n\n1. No cancer found\n2. Age greater than 18 years -",{"count":379,"type":21},10000,"12 Months","The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population.\n\nCollecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.",[383],"Pediatric Cancer","2025-09-29",{"date":386,"type":35},"2025-10-03",{"date":388,"type":35},"2016-01-01",{"date":390,"type":21},"2030-12",{"name":301,"class":122},14,{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":50,"sex":16,"minAge":400,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":71},"100582197","phase-4-integrating-malaria-vaccine-with-seasonal-malaria-chemoprevention-in-west-africa-100582197","NCT06860178","Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa","IMVACS","Inclusion criteria:\n\nControl arms :\n\n* Children aged 5-36 months in Burkina Faso and Mali at the time of first study vaccination;\n* Resident in the catchment area of a health centre assigned to the control arm;\n* Willingness to comply with the study procedures;\n* Written informed consent from Parent\u002FGuardian.\n\nIntervention arms :\n\n* Children aged 3-59 months at the time of first study vaccination;\n* Resident in the catchment area of a health centre assigned to the intervention arm;\n* Willingness to comply with the study procedures;\n* Written informed consent from Parent\u002FGuardian.\n\nExclusion Criteria:\n\n1. History of allergic disease or reactions likely to be exacerbated by any component of the Vaccines;\n2. Any history of anaphylaxis in relation to vaccination;\n3. Known chronic illness;\n4. Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial;\n5. History of vaccination with another malaria vaccine. -","3 Months","59 Months",{"count":403,"type":21},40000,[405],"PHASE4","This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21 malaria vaccine alongside SMC among children in areas with highly seasonal malaria transmission. In this study, a cluster is defined as the catchment area of a health centre. Clusters will be randomised to receive either year-round age-based routine EPI vaccination for children aged 5-36 months (\"Routine EPI Vaccination\") in Burkina Faso or an annual campaign of the 3-dose primary series in children aged 5-36 months prior to the malaria season and SMC delivery (''Routine Pre-SMC vaccination'') in Mali versus an annual campaign of the 3-dose primary series aligned with SMC distribution in children aged 3-59 months (\"Integrated SMC Vaccination\") in each country. Effectiveness will be assessed in terms of clinical malaria, vaccine coverage, acceptability, feasibility, and cost-effectiveness.\n\nMalaria incidence will be determined using routine surveillance activities for clinical malaria detection and reporting in each country. Cross-sectional surveys will be conducted to determine the prevalence of parasitaemia in the communities. In addition, the acceptability, feasibility, coverage and cost-effectiveness of the different delivery systems of R21\u002FMatrix-M will be assessed.",[408],"Malaria Vaccine",[198,410,411,412,413],"CPS","pediatric","vaccine","R21","2025-08-05",{"date":416,"type":35},"2025-08-08",{"date":418,"type":35},"2025-06-10",{"date":420,"type":21},"2027-12",{"name":422,"class":122},"Epicentre",""]